Get the latest news alerts: at Twitter.
Local Tech Wire
RALEIGH, N.C. – is retaining ICR, a Connecticut-based firm with offices across the U.S. and in China, to handle its investor relations.
BioDelivery (Nasdaq: BDSI) recently received U.S. Food and Drug Administration approval for Onsolis, a treatment of breakthrough cancer pain.
The press release:
RALEIGH, N.C.- BioDelivery Sciences International, Inc. (BDSI®) (Nasdaq:BDSI) today announced that it has retained ICR, a leading investor relations and strategic advisory firm, to assist in the Company’s shareholder communications program. ICR, founded in 1998 by a group of former institutional capital markets professionals, is headquartered in Westport, Connecticut, with offices in Westport, New York, Los Angeles, Boston, Chicago, Minneapolis, Beijing, and Shanghai.
“With the recent approval and upcoming launch of ONSOLIS™, we are at a very exciting point in BDSI’s development and look forward to partnering with ICR to enhance our communications outreach efforts,” stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences. “With strong knowledge of the capital markets and an extensive background in the healthcare sector, we believe the team at ICR, led by Dr. Donald Ellis, will be instrumental in effectively communicating our business model and growth strategy as well as raising awareness of BDSI within the investment community. We look forward to working with the team at ICR as we execute our growth plan and seek to build shareholder value over the long term.”
Prior to joining ICR, Donald Ellis was a Senior Sell-Side Equities Research Analyst for fifteen years covering the specialty pharmaceutical and drug delivery sectors. Before entering the securities business, Donald spent ten years in clinical practice at Kaiser Permanente and at the Veterans Administration Hospital in San Diego, California.